Literature DB >> 18465358

Insulin analogues: action profiles beyond glycaemic control.

Kristin Eckardt1, Jürgen Eckel.   

Abstract

A variety of studies have documented significant improvements in the treatment of type 1 and 2 diabetes after the introduction of artificial insulins. This review gives an overview of insulin analogues which are currently approved for therapeutical use. Clinical data regarding the efficiency to control blood glucose level as well as improving HbA1c level in comparison to conventional insulin preparations in type 1 and 2 diabetic patients are summarized. Furthermore, special features of insulin analogues regarding their signalling properties are discussed with focus on the proliferative effects of insulin glargine as well as some recent data of insulin detemir.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18465358     DOI: 10.1080/13813450801983369

Source DB:  PubMed          Journal:  Arch Physiol Biochem        ISSN: 1381-3455            Impact factor:   4.076


  4 in total

1.  In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.

Authors:  Mark R Sommerfeld; Günter Müller; Georg Tschank; Gerhard Seipke; Paul Habermann; Roland Kurrle; Norbert Tennagels
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

2.  Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years.

Authors:  Haim Werner; Ernst A Chantelau
Journal:  Diabetol Metab Syndr       Date:  2011-06-29       Impact factor: 3.320

Review 3.  Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps.

Authors:  Vasiliki Valla
Journal:  Exp Diabetes Res       Date:  2010-05-26

4.  Sensitivity of human pluripotent stem cells to insulin precipitation induced by peristaltic pump-based medium circulation: considerations on process development.

Authors:  Diana Massai; Emiliano Bolesani; Diana Robles Diaz; Christina Kropp; Henning Kempf; Caroline Halloin; Ulrich Martin; Tudor Braniste; Giuseppe Isu; Vanessa Harms; Umberto Morbiducci; Gerald Dräger; Robert Zweigerdt
Journal:  Sci Rep       Date:  2017-06-21       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.